ImmunityBio
IBRX----
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: ImmunityBio(IBRX) predict that the Revenue is 44.21 M (+167.6%), Beat estimate;the EBIT is -69.79 M (-8.32%), Miss estimate;the EPS is -0.62 (-313.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.04B167.64%
0.04B166.01%
+0.00B1.63%
EBITMiss expectations
-0.07B8.32%
-0.06B9.94%
-0.01B18.26%
EPSMiss expectations
-0.62313.33%
-0.0753.33%
-0.5500366.66%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf